shanghai fosun pharmaceutical

Fosun & Partner For Pharma E-Commerce

The cooperation agreement between Fosun Pharmaceuticals and is expected to expand’s pharmaceutical e-commerce platform.

Chinese Consortium Acquires Ambrx For Undisclosed Sum

The acquisition of Ambrx adds bio-conjugation capabilities to the WuXi PharmaTech-led consortium.

Reducing Malaria-Ebola Cross Infections

Guilin Pharma has increased its supply of anti-malarial drugs to Sub-Saharan Africa to reduce Ebola cross-infections.

Fosun Commits US$111 Million To Partnership With Public Hospital

The partnership between Fosun and Taizhou Muncipal Hospital will add approximately 2,000 new hospital beds to serve the residents of Taizhou.

Artemether, Guilin Pharma’s First WHO-certified API

Guilin Pharma has received its first WHO product quality certification for the anti-malaria drug Artemether, paving the way for other drugs in its portfolio.

Fosun Pharma Granted License For TB Alliance Drug

The public-private partnership between the Gates Foundation, TB alliance and Fosun Pharma aims to develop and commercialize a new TB drug in China.

Chindex To Merge With Fosun Pharma At Higher Share Price

Fosun Pharma and TPG increase their bid for Chindex from US$19.50 to US$24.00 per share.

Fosun Pharma And TPG To Acquire Chindex

Shanghai Fosun Pharmaceutical and TPG will acquire Chindex International for approximately $394 million.

Sirona Biochem Signs LOI With Wanbang Pharma

Sirona Biochem has signed a LOI with Wanbang Pharma to develop and commercialize its SGLT2 inhibitor in China.